## Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

- 1. (Previously presented) An immunogenic complex, comprising a negatively-charged organic complex and a positively-charged antigen, where (A) said organic complex comprises a saponin and a sterol and (B) said organic complex and antigen are electrostatically associated.
  - 2. (Canceled)
- 3. (Currently amended) The immunogenic complex according to claim 1 [[2]] wherein said antigen is a protein or comprises a peptide region.
  - 4-5. (Canceled)
- 6. (Previously presented) The immunogenic complex according to claim 1 wherein said organic complex is a naturally negatively charged complex which has been modified to increase the degree of its negative charge.
- 7. (Previously presented) The immunogenic complex according to claim 1 wherein said antigen has been modified to increase the degree of its positive charge.
- 8. (Previously presented) The immunogenic complex according to claim 3 wherein said organic complex is a naturally negatively charged complex which has been modified to increase the degree of its negative charge and said antigen is a naturally positively charged antigen which has been modified to increase the degree of its positive charge.
  - 9-11. (Canceled)
- 12. (Previously presented) The immunogenic complex according to claim 1 wherein the organic complex further comprises a phospholipid.
- 13. (Previously presented) The immunogenic complex according to claim 12 wherein said phospholipid is a phosphoglyceride.
- 14. (Previously presented) The immunogenic complex according to claim 13 wherein the phosphoglyceride is selected from the group consisting of phosphatidyl inositol, phosphatidyl glycerol, phosphatidic acid and cardiolipin.

- 15. (Previously presented) The immunogenic complex according to claim 12 wherein said phospholipid is lipid A.
- 16. (Previously presented) The immunogenic complex according to claim 15 wherein the lipid A is selected from the group consisting of diphosphoryl lipid A and monophosphoryl lipid A.
- 17. (Previously presented) The immunogenic complex according to claim 1, wherein said immunogenic complex induces a cytotoxic T-lymphocyte response when administered to a mammal.

## 18-52. (Canceled)

organic complex and a positively-charged antigen, where (A) said organic complex and said antigen are electrostatically associated and (B) said complex generates a cytotoxic CTL response when administered to a mammal, wherein (i) the organic complex comprises a saponin and a sterol, and (ii) the organic complex is modified to increase the degree of its negative charge and/or the antigen is modified to increase the degree of its positive charge.